[go: up one dir, main page]

NL1028310A1 - Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen. - Google Patents

Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.

Info

Publication number
NL1028310A1
NL1028310A1 NL1028310A NL1028310A NL1028310A1 NL 1028310 A1 NL1028310 A1 NL 1028310A1 NL 1028310 A NL1028310 A NL 1028310A NL 1028310 A NL1028310 A NL 1028310A NL 1028310 A1 NL1028310 A1 NL 1028310A1
Authority
NL
Netherlands
Prior art keywords
compounds useful
inflammatory conditions
treating inflammatory
benzopyran compounds
benzopyran
Prior art date
Application number
NL1028310A
Other languages
English (en)
Other versions
NL1028310C2 (nl
Inventor
Jeffery Steven Carter
Karl William Aston
David Louis Brown
Angela M Deprow
Theresa R Fletcher
E Ann Hallinan
Bruce Cameron Hamper
Renee M Huff
James Richard Kiefer Jr
Francis Koszyk
Steven W Kramer
Subo Liao
David Christopher Limburg
Cindy Ludwig
John Michael Mccall
John Robert Springer
John T Taley
Lijuan Jane Wang
Li Xing
Yi Yu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NL1028310A1 publication Critical patent/NL1028310A1/nl
Application granted granted Critical
Publication of NL1028310C2 publication Critical patent/NL1028310C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
NL1028310A 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen. NL1028310C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45921503P 2003-03-31 2003-03-31
US45921503 2003-03-31

Publications (2)

Publication Number Publication Date
NL1028310A1 true NL1028310A1 (nl) 2005-03-09
NL1028310C2 NL1028310C2 (nl) 2005-11-16

Family

ID=33131871

Family Applications (9)

Application Number Title Priority Date Filing Date
NL1025843A NL1025843C2 (nl) 2003-03-31 2004-03-29 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028307A NL1028307C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028306A NL1028306C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028310A NL1028310C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028308A NL1028308C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028304A NL1028304C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028309A NL1028309C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028305A NL1028305C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028303A NL1028303C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NL1025843A NL1025843C2 (nl) 2003-03-31 2004-03-29 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028307A NL1028307C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028306A NL1028306C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.

Family Applications After (5)

Application Number Title Priority Date Filing Date
NL1028308A NL1028308C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028304A NL1028304C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028309A NL1028309C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028305A NL1028305C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1028303A NL1028303C2 (nl) 2003-03-31 2005-02-16 Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.

Country Status (25)

Country Link
US (1) US7259266B2 (nl)
EP (1) EP1615905A2 (nl)
JP (1) JP2006522098A (nl)
KR (1) KR20060015490A (nl)
CN (1) CN1768050A (nl)
AR (1) AR044207A1 (nl)
AU (1) AU2004226164A1 (nl)
BR (1) BRPI0408388A (nl)
CA (1) CA2520724A1 (nl)
EA (1) EA200501399A1 (nl)
EC (2) ECSP056064A (nl)
IS (1) IS7995A (nl)
MA (1) MA27725A1 (nl)
MX (1) MXPA05010630A (nl)
NL (9) NL1025843C2 (nl)
NO (1) NO20054121L (nl)
OA (1) OA13112A (nl)
PA (1) PA8599601A1 (nl)
PE (1) PE20050012A1 (nl)
RS (1) RS20050744A (nl)
TN (1) TNSN05249A1 (nl)
TW (1) TWI257927B (nl)
UY (1) UY28252A1 (nl)
WO (1) WO2004087686A2 (nl)
ZA (1) ZA200506551B (nl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CA2574363A1 (en) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Enantioselective method for separating sustituted 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
WO2006011052A1 (en) * 2004-07-23 2006-02-02 Pharmacia & Upjohn Company Llc Method for the racemization of 2-trifluoro-2h-chromene-3-carboxylic acids
EP1778662A1 (en) * 2004-07-23 2007-05-02 Warner-Lambert Company LLC Photoracemization of 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives
EP1792887A1 (en) * 2005-12-05 2007-06-06 Laboratorios Del Dr. Esteve, S.A. Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems
WO2009079011A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
JP2011507850A (ja) * 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
EP2234618A4 (en) * 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
CN102757417B (zh) * 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
EP2860177A3 (en) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
EP3052482A1 (en) * 2013-09-30 2016-08-10 Polfarmex S.A. Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2015109013A1 (en) * 2014-01-14 2015-07-23 Euclises Pharmaceuticals, Inc. Deuterated no-releasing nitrooxy-chromene conjugates
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺
US12521201B2 (en) 2017-12-07 2026-01-13 Augmedics Ltd. Spinous process clamp
US12458411B2 (en) 2017-12-07 2025-11-04 Augmedics Ltd. Spinous process clamp
US11980507B2 (en) 2018-05-02 2024-05-14 Augmedics Ltd. Registration of a fiducial marker for an augmented reality system
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US12178666B2 (en) 2019-07-29 2024-12-31 Augmedics Ltd. Fiducial marker
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US11389252B2 (en) 2020-06-15 2022-07-19 Augmedics Ltd. Rotating marker for image guided surgery
US12239385B2 (en) 2020-09-09 2025-03-04 Augmedics Ltd. Universal tool adapter
US12502163B2 (en) 2020-09-09 2025-12-23 Augmedics Ltd. Universal tool adapter for image-guided surgery
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
US12150821B2 (en) 2021-07-29 2024-11-26 Augmedics Ltd. Rotating marker and adapter for image-guided surgery
US20240308988A1 (en) 2021-08-05 2024-09-19 Syngenta Crop Protection Ag Method For Controlling Diamide Resistant Pests and Compounds Therefor
US12475662B2 (en) 2021-08-18 2025-11-18 Augmedics Ltd. Stereoscopic display and digital loupe for augmented-reality near-eye display
EP4511809A1 (en) 2022-04-21 2025-02-26 Augmedics Ltd. Systems and methods for medical image visualization
IL319523A (en) 2022-09-13 2025-05-01 Augmedics Ltd Augmented reality glasses for image-guided medical intervention
CN116903457A (zh) * 2023-07-18 2023-10-20 上海添泽生物医药有限公司 一种2-羟基-5-异丙基苯甲酸的合成方法
CN119285593B (zh) * 2024-10-08 2025-09-23 河南农业大学 苯并吡喃类衍生物、合成方法及应用
CN119954759B (zh) * 2025-01-03 2025-10-21 安炎达医药技术(广州)有限公司 一种苯并吡喃类cox-2抑制剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20030153801A1 (en) 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
US6620871B2 (en) * 2001-06-07 2003-09-16 Nike, Inc. Rubber compositions with increased shelf life and reduced cure temperatures and times
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor

Also Published As

Publication number Publication date
NL1028310C2 (nl) 2005-11-16
BRPI0408388A (pt) 2006-03-01
KR20060015490A (ko) 2006-02-17
NL1028309C2 (nl) 2005-11-16
AU2004226164A1 (en) 2004-10-14
JP2006522098A (ja) 2006-09-28
OA13112A (en) 2006-11-10
NL1028305C2 (nl) 2005-11-16
AR044207A1 (es) 2005-09-07
ECSP056063A (es) 2006-01-27
WO2004087686A3 (en) 2004-12-16
NL1028303A1 (nl) 2005-03-09
WO2004087686A2 (en) 2004-10-14
PA8599601A1 (es) 2005-05-24
NL1028309A1 (nl) 2005-03-09
NL1028308A1 (nl) 2005-03-09
RS20050744A (sr) 2007-08-03
NL1025843A1 (nl) 2004-10-01
NO20054121L (no) 2005-12-20
NL1028306C2 (nl) 2005-11-16
MA27725A1 (fr) 2006-01-02
CA2520724A1 (en) 2004-10-14
TNSN05249A1 (fr) 2007-06-11
EP1615905A2 (en) 2006-01-18
NL1025843C2 (nl) 2005-03-01
IS7995A (is) 2005-08-18
UY28252A1 (es) 2004-11-08
CN1768050A (zh) 2006-05-03
EA200501399A1 (ru) 2006-04-28
MXPA05010630A (es) 2005-12-12
NL1028304A1 (nl) 2005-03-09
US20050148777A1 (en) 2005-07-07
PE20050012A1 (es) 2005-03-12
ZA200506551B (en) 2006-11-29
NL1028304C2 (nl) 2005-11-16
NL1028307A1 (nl) 2005-03-09
NL1028308C2 (nl) 2005-11-16
TW200510365A (en) 2005-03-16
NO20054121D0 (no) 2005-09-05
US7259266B2 (en) 2007-08-21
TWI257927B (en) 2006-07-11
NL1028307C2 (nl) 2005-11-16
NL1028305A1 (nl) 2005-03-09
NL1028303C2 (nl) 2005-11-16
ECSP056064A (es) 2006-01-27
NL1028306A1 (nl) 2005-03-09

Similar Documents

Publication Publication Date Title
NL1028308A1 (nl) Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NL1023695A1 (nl) Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
NL1023692A1 (nl) Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
NL1023693A1 (nl) Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
NL1023691A1 (nl) Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
NL1023694A1 (nl) Werkwijze voor het zuiveren van Fischer-Tropsch-afkomstig water.
IS8345A (is) 6-útskipt anilínópúrín sem RTK-tálmar
NL1030819A1 (nl) Nieuwe pyrrolidylderivaten van heteroaromatische verbindingen.
NL1022210A1 (nl) Systeem voor het vervaardigen van halfgeleiderproducten.
NL1028397A1 (nl) Werkwijze voor automatisch bepalen van het sagittale vlak.
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
NL1021625A1 (nl) Werkwijze voor het beperken van de mogelijkheid tot bekijken.
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
NL1017831A1 (nl) Werkwijze voor het conserveren van lichtgevoelige samenstelling.
DE60313502D1 (de) 180-grad-regler
NL1032552C2 (nl) Imidazoolverbindingen voor de behandeling van neurologische stoornissen.
NL1028646A1 (nl) Inrichting voor het inspecteren van metalen oppervlakken.
NL1031680A1 (nl) Startapparaat voor autogasvoertuig en werkwijze voor aansturing daarvan.
EP1804796A4 (en) AMINO-SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES
NL1021718A1 (nl) Multifunctionele dompelarmatuur voor het bepalen van meetparameters.
FI20030467A0 (fi) Menetelmä tulehdustilojen hoitamiseen
NL1030417A1 (nl) Azabenzoxazolen voor de behandeling van aandoeningen van het CZS.

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20050630

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20081001